线粒体相关的编程细胞死亡:阐明多发性骨髓瘤的预后生物标志物,免疫检查点和治疗途径
Gongzhizi Gao1, Jiyu Miao1, Yachun Jia1
1Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Frontiers in immunology
|December 27, 2024
概括
七个关键基因参与线粒体功能和编程细胞死亡 (PCD) 被确定为多发性骨髓瘤 (MM) 的预后标志物. 这项研究提供了关于MM进展和潜在的新治疗点的见解.
科学领域:
- 血液学的恶性瘤
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 多发性骨髓瘤 (MM) 是一种血细胞恶性瘤.
- 线粒体功能障碍和编程细胞死亡 (PCD) 途径与MM病变产生有关.
- 在MM中,线粒体相关基因 (MRG) 和PCD相关基因 (PCDRG) 的预后意义尚未完全理解.
研究的目的:
- 在多发性髓瘤中识别与线粒体和PCD相关的预后基因.
- 开发一个MM患者生存率的预测模型.
- 探索预后基因,免疫透和药物反应之间的关系.
主要方法:
- 来自MM患者和健康对照组的转录组数据的差异基因表达分析.
- 不同表达基因 (DEG) 与MRG和PCDRG的交叉.
- 考克斯,LASSO和逐步回归的应用用于预后基因鉴定.
- 为生存预测和验证构建风险模型和名图.
主要成果:
- 七个基因 (TRIAP1,TOMM7,PINK1,CHCHD10,PPIF,BCL2L1,NDUFA13) 被确定为重要的预后标记物.
- 一个风险模型有效地将MM患者分为高风险和低风险组.
- 诺米图表显示了对患者结果的良好预测准确性.
- 在预后基因,免疫细胞透和药物反应之间发现了关联.
结论:
- 鉴定到的七个基因是多发性骨髓瘤的关键预后标志物.
- 这些发现提高了对MM生物学和预后的理解.
- 该研究强调了MM治疗的潜在新疗法目标.
相关概念视频
01:31The Intrinsic Apoptotic Pathway
5.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.5K
02:23Abnormal Proliferation
4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
03:03mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
01:15Differentiation of Common Myeloid Progenitor Cells
3.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.1K